Balkrishna Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 8, 2025, 5:49 am

Competitors of Balkrishna Industries Ltd

All Competitor Stocks of Balkrishna Industries Ltd

Quarterly Result

Last Updated: August 1, 2025, 11:40 pm

Below is a detailed analysis of the quarterly data for Balkrishna Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 2,760.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,752.00 Cr. (Mar 2025) to 2,760.00 Cr., marking an increase of 8.00 Cr..
• For Expenses, as of Jun 2025, the value is 2,254.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,139.00 Cr. (Mar 2025) to 2,254.00 Cr., marking an increase of 115.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 506.00 Cr.. The value appears to be declining and may need further review. It has decreased from 614.00 Cr. (Mar 2025) to 506.00 Cr., marking a decrease of 108.00 Cr..
• For OPM %, as of Jun 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Mar 2025) to 18.00%, marking a decrease of 4.00%.
• For Other Income, as of Jun 2025, the value is 107.00 Cr.. The value appears strong and on an upward trend. It has increased from 99.00 Cr. (Mar 2025) to 107.00 Cr., marking an increase of 8.00 Cr..
• For Interest, as of Jun 2025, the value is 31.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 50.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 19.00 Cr..
• For Depreciation, as of Jun 2025, the value is 188.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 178.00 Cr. (Mar 2025) to 188.00 Cr., marking an increase of 10.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 394.00 Cr.. The value appears to be declining and may need further review. It has decreased from 485.00 Cr. (Mar 2025) to 394.00 Cr., marking a decrease of 91.00 Cr..
• For Tax %, as of Jun 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 27.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 288.00 Cr.. The value appears to be declining and may need further review. It has decreased from 369.00 Cr. (Mar 2025) to 288.00 Cr., marking a decrease of 81.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 14.91. The value appears to be declining and may need further review. It has decreased from 19.06 (Mar 2025) to 14.91, marking a decrease of 4.15.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:27 pm

Growth

Last Updated: September 5, 2025, 12:25 am

Balance Sheet

Last Updated: June 16, 2025, 12:25 pm

Below is a detailed analysis of the balance sheet data for Balkrishna Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 39.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 39.00 Cr..
• For Reserves, as of Mar 2025, the value is 10,349.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,815.00 Cr. (Mar 2024) to 10,349.00 Cr., marking an increase of 1,534.00 Cr..
• For Borrowings, as of Mar 2025, the value is 3,267.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3,099.00 Cr. (Mar 2024) to 3,267.00 Cr., marking an increase of 168.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,980.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,731.00 Cr. (Mar 2024) to 1,980.00 Cr., marking an increase of 249.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 15,635.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13,685.00 Cr. (Mar 2024) to 15,635.00 Cr., marking an increase of 1,950.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 6,941.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,317.00 Cr. (Mar 2024) to 6,941.00 Cr., marking an increase of 624.00 Cr..
• For CWIP, as of Mar 2025, the value is 986.00 Cr.. The value appears strong and on an upward trend. It has increased from 944.00 Cr. (Mar 2024) to 986.00 Cr., marking an increase of 42.00 Cr..
• For Investments, as of Mar 2025, the value is 3,264.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,686.00 Cr. (Mar 2024) to 3,264.00 Cr., marking an increase of 578.00 Cr..
• For Other Assets, as of Mar 2025, the value is 4,443.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,737.00 Cr. (Mar 2024) to 4,443.00 Cr., marking an increase of 706.00 Cr..
• For Total Assets, as of Mar 2025, the value is 15,635.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,685.00 Cr. (Mar 2024) to 15,635.00 Cr., marking an increase of 1,950.00 Cr..

Notably, the Reserves (10,349.00 Cr.) exceed the Borrowings (3,267.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Balkrishna Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 85.61. This value is within the healthy range. It has increased from 76.12 (Mar 24) to 85.61, marking an increase of 9.49.
• For Diluted EPS (Rs.), as of Mar 25, the value is 85.61. This value is within the healthy range. It has increased from 76.12 (Mar 24) to 85.61, marking an increase of 9.49.
• For Cash EPS (Rs.), as of Mar 25, the value is 120.83. This value is within the healthy range. It has increased from 109.79 (Mar 24) to 120.83, marking an increase of 11.04.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 537.38. It has increased from 458.04 (Mar 24) to 537.38, marking an increase of 79.34.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 537.38. It has increased from 458.04 (Mar 24) to 537.38, marking an increase of 79.34.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 540.45. It has increased from 484.68 (Mar 24) to 540.45, marking an increase of 55.77.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 155.01. This value is within the healthy range. It has increased from 139.92 (Mar 24) to 155.01, marking an increase of 15.09.
• For PBIT / Share (Rs.), as of Mar 25, the value is 119.80. This value is within the healthy range. It has increased from 106.25 (Mar 24) to 119.80, marking an increase of 13.55.
• For PBT / Share (Rs.), as of Mar 25, the value is 113.16. This value is within the healthy range. It has increased from 100.41 (Mar 24) to 113.16, marking an increase of 12.75.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 85.62. This value is within the healthy range. It has increased from 76.12 (Mar 24) to 85.62, marking an increase of 9.50.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 85.62. This value is within the healthy range. It has increased from 76.12 (Mar 24) to 85.62, marking an increase of 9.50.
• For PBDIT Margin (%), as of Mar 25, the value is 28.68. This value is within the healthy range. It has decreased from 28.86 (Mar 24) to 28.68, marking a decrease of 0.18.
• For PBIT Margin (%), as of Mar 25, the value is 22.16. This value exceeds the healthy maximum of 20. It has increased from 21.92 (Mar 24) to 22.16, marking an increase of 0.24.
• For PBT Margin (%), as of Mar 25, the value is 20.93. This value is within the healthy range. It has increased from 20.71 (Mar 24) to 20.93, marking an increase of 0.22.
• For Net Profit Margin (%), as of Mar 25, the value is 15.84. This value exceeds the healthy maximum of 10. It has increased from 15.70 (Mar 24) to 15.84, marking an increase of 0.14.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.84. This value is within the healthy range. It has increased from 15.70 (Mar 24) to 15.84, marking an increase of 0.14.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.93. This value is within the healthy range. It has decreased from 16.61 (Mar 24) to 15.93, marking a decrease of 0.68.
• For Return on Capital Employeed (%), as of Mar 25, the value is 20.29. This value is within the healthy range. It has decreased from 20.48 (Mar 24) to 20.29, marking a decrease of 0.19.
• For Return On Assets (%), as of Mar 25, the value is 10.58. This value is within the healthy range. It has decreased from 10.75 (Mar 24) to 10.58, marking a decrease of 0.17.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.03, marking a decrease of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.31. This value is within the healthy range. It has decreased from 0.34 (Mar 24) to 0.31, marking a decrease of 0.03.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. There is no change compared to the previous period (Mar 24) which recorded 0.71.
• For Current Ratio (X), as of Mar 25, the value is 1.32. This value is below the healthy minimum of 1.5. It has increased from 1.27 (Mar 24) to 1.32, marking an increase of 0.05.
• For Quick Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has decreased from 0.90 (Mar 24) to 0.89, marking a decrease of 0.01.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.20. This value is below the healthy minimum of 4. It has increased from 2.94 (Mar 24) to 3.20, marking an increase of 0.26.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.68. This value is below the healthy minimum of 20. It has decreased from 21.01 (Mar 24) to 18.68, marking a decrease of 2.33.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.24. This value is below the healthy minimum of 20. It has decreased from 14.57 (Mar 24) to 13.24, marking a decrease of 1.33.
• For Earning Retention Ratio (%), as of Mar 25, the value is 81.32. This value exceeds the healthy maximum of 70. It has increased from 78.99 (Mar 24) to 81.32, marking an increase of 2.33.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 86.76. This value exceeds the healthy maximum of 70. It has increased from 85.43 (Mar 24) to 86.76, marking an increase of 1.33.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 23.35. This value is within the healthy range. It has decreased from 23.96 (Mar 24) to 23.35, marking a decrease of 0.61.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 13.90. This value is within the healthy range. It has decreased from 14.04 (Mar 24) to 13.90, marking a decrease of 0.14.
• For Enterprise Value (Cr.), as of Mar 25, the value is 52,453.30. It has increased from 47,822.37 (Mar 24) to 52,453.30, marking an increase of 4,630.93.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.02. This value exceeds the healthy maximum of 3. It has decreased from 5.10 (Mar 24) to 5.02, marking a decrease of 0.08.
• For EV / EBITDA (X), as of Mar 25, the value is 17.51. This value exceeds the healthy maximum of 15. It has decreased from 17.68 (Mar 24) to 17.51, marking a decrease of 0.17.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.72. This value exceeds the healthy maximum of 3. It has decreased from 4.78 (Mar 24) to 4.72, marking a decrease of 0.06.
• For Retention Ratios (%), as of Mar 25, the value is 81.31. This value exceeds the healthy maximum of 70. It has increased from 78.98 (Mar 24) to 81.31, marking an increase of 2.33.
• For Price / BV (X), as of Mar 25, the value is 4.74. This value exceeds the healthy maximum of 3. It has decreased from 5.06 (Mar 24) to 4.74, marking a decrease of 0.32.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.72. This value exceeds the healthy maximum of 3. It has decreased from 4.78 (Mar 24) to 4.72, marking a decrease of 0.06.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness